A 12-month, randomized, placebo-controlled trial of propentofylline (hwa 285) in patients with dementia according to DSM III-R

Dementia and Geriatric Cognitive Disorders

Volumn 8, Issue 5, 1997, Pages 320-328

  Marcusson, J ^a   Rother, M ^a   Kittner, B ^a   Rossner M ^a   Smith, R J ^a   Babic, T ^a   Folnegovic Smalc V ^a   Moller H J ^a   Labs, K H ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer s disease; Dementia; Propentofylline; Treatment; Vascular dementia

Indexed keywords

CALCIUM ION; FREE RADICAL; GLUTAMIC ACID; PROPENTOFYLLINE; VASODILATOR AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CELL ACTIVITY; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; VERTIGO;

EID: 0030879207     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000106650     Document Type: Article

References (32)

1. Esiri MM, Wilcock GK: Cerebral amyloid angiopathy in dementia and old age, Neurol Neu-rosurg Psychiatry 1986;49:1221-1226.
2. Wallin A, Alafuzof TI, Carlsson A, Eckemäs SÀ, Gottfries C-G, Karlsson I, Svcnnerholm L, Winblad B: Neurotransmitter deficits in a non-multi-infarct category of vascular dementia, Acta Neurol Scand 1989:79:397-406.
3. Beal M, Flint M: Mechanisms of excilotoxicity in neurologic diseases, FASEB J 1991:6:3338-3344.
4. Sicsjo BK: Pathophysiology and treatment of focal brain ischemia, 11, Mechanism of damage and treatment, J Neurosurg 1992;7:337-354
5. Friedlich AL, Butcher LL: Involvement office oxygen radicals in bcta-amyloidosis: A hypothesis, Neurobiol Aging 1994:15:443-455.
6. Banaii RB, Gehrmann J, Schubert P, Krcutz-bcrg GW: Cytotoxicity of microglia, Glia 1993: 7:111-118.
7. McGcer P, Rogers J: Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease, Neurology1992:42:447-449.
8. Parkinson FE, Rudolphi KA, Fredholm BB: HWA 285: A nucleoside transport inhibitor with ncuroprotectivc effects in cerebral ischemia, Gen Pharmacol 1994;6:1053-1058
9. Banaii RB, Schubert P, Rothe G, Gehrmann J, Rudolphi K, Valet G, Krcutzberg GW: Modulation of intracellular formation of reactive oxygen intermediates in peritoneal macrophages and microglia/brain macrophages by HWA 285, J Ccreb Blood Flow Mctab 1994; 14:145-149.
10. McRae A, Rudolphi KA, Schubert P: HWA 285 depresses amyloid and Alzheimer's CSF microglial antigens after ischemia, Neuroreport 1994;5:1193-1196.
11. Fuji K, Hiramatsu M, Hayashi S, Kamcyama T, Nabeshima T: Effects of IIWA 285, a NGF synthesis stimulator, on alterations in muscarinic cholinergic receptors induced by basal forebrain lesions in rats, Neurosci Lett 1993: 150:99-102.
12. Goto M, Demura N, Sakaguchi T: Effects of HWA 285 on disorder of learning and memory in rodents, Jpn J Pharmacol 1987:45:373-378
13. Yamada Y, Nakamura H, Okada Y: HWA 285 enhances the formation of long-term potentiation in guinea pig hippocampal slices, Neurosci Lett 1994;176:189-192.
14. Shinoda I, Furukawa Y, Furukawa S: Stimulation of nerve growth factor synthesis/secretion by HWA 285 in cultured mouse astroglial cells, Biochcnt Pharmacol 1990:39:1813-1816
15. Nabeshima T, Nitta A, Hascgawa T: Impairment ofleaming and memory and the accessory symptoms in aged rats as senile dementia model, 3: Oral administration of HWA 285 produces recovery of reduced NGF content in the brain of aged rat, Jpn J Psychopharmacol 1993;13:89-95.
16. Môller HJ, Maurer I, Saletu B: Placebo-controlled trial of the xanthine derivative HWA 285 in dementia, Pharmacopsvchiatrv 1994; 27:159-165.
17. CGI-Clinical Global Impressions: in Guy W, (ed): ECDEU Assessment for Psychopharmacology, Rockville, National Institute of Mental Health 1976, pp 217-222.
18. Folstein MF, Folstcin SE, McHough PR: Mini-Mental State: A practical method for grading the cognitive state of patients for clinicians, J PsychiatrRcs 1975:12:189-198.
19. Diagnostic and statistical manual of mental disorders, 3rd rev, DSM UI-R, American Psychiatric Association, Washington, 1987
20. Hachinski VC, Iliflf LD, Zilhka E, Du Boulay GH, Me Allistcr VL, Marshall J, Russcscll RW, Symon L: Cerebral blood flow in dementia, Arch Neurol 1975:32:632-637.
21. Goltfries CG, Brine G, Gullberg B, Steen G: A new rating scale for dementia syndrome, Arch Gerontol Geriatr 1982; 1:311-330.
22. Erzigkeit H: SKT: Ein Kürztest zur Erfassung von Gedächtnis- und Aufmerksamkeitsstörungen, Erlangen, 1986.
23. Oswald WD, Fleischmann UM: Nürnberger Altcrsinvcntar NA1, Nürnberg, Universität Er-langen-Nümberg, 1986.
24. Zerssen D von, Kodier D-M, Rey E-R: Die Bcfindlichkeitsskala (BfS), ein einfaches Instrument zur Objektivierung von Befindlichkeits-Störungen, insbesondere im Rahmen von Längsschnitt-Untersuchungen, Arzneimittcl-forschung 1970:20:915-918.
25. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies, J Natl Cancer Inst 1959:22:719-748.
26. Kim YS, Nibbelink DW, Overall JE: Factor structure and scoring and the SKT lest battery, J Clin Psychol 1993:49:61-71.
27. Ihl R, Fröhlich L, Dicrks T, Martin E-M, Maurer K: Differential Validity of Psychometric Tests in Dementia of the Alzheimer Type, Psychiatry Res 106 1992,93-106.
28. Galasko D, Corey-Bloom J, Thal U: Monitoring progression in Alzheimer's disease, J Am Geriatr Soc 1991;39:932-941.
29. McKhann G, Drachman D, Folstein M, Katz-man R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease, Neurology 1984;34:939-949.
30. ICD-10, Classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines, Geneva, World Health Organisation, Division of Mental Health, 1993
31. Empfehlungen für Wirksamkeitsnachweis fur Nootropika im Indikationsbereich Demenz (Phase III), Gemeinsames Papier der das Bundesgesundheitsamt beratenden Zulassungskommission für neue Stoffe (Kommission A) und der Aufbereitungskommission Neurologie, Psychiatric (Kommission B3), Bundesgesund-heitsblalt 1991;7:342-350.
32. Dowcn DM, Davison AN: Can the pathophysiology of dementia lead to rational therapy? In: Crook T, Bartus R, Ferris S, Garshon S (eds): Treatment Development Strategies for Alzheimer's Disease, Madison, Mark Powlcy Associates, 1986, pp 36-66.